Eli Lilly and Company (NYSE: LLY) announced results from the long-term extension (LTE) of the Phase 3 TRAILBLAZER-ALZ 2 study ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, ...

Cognition Therapeutics’ therapy showed up to a 129% slowing of cognitive decline in mild Alzheimer’s disease patients.

"We discovered that bacteria all around us are using amyloids as a molecular suit of armor," said senior author Aaron Whiteley, assistant professor in the Department of Biochemistry.

For older adults who may otherwise be food-insecure, participating in food assistance benefits may be associated with a ...